Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the prior position statements, published in 2012 and 2015, on …

415 million people live with diabetes worldwide, and an estimated 193 million people have
undiagnosed diabetes. Type 2 diabetes accounts for more than 90% of patients with …

Methods Medline, Embase and the Cochrane Library databases were searched for terms
related to sedentary time and health outcomes. Cross-sectional and prospective studies were …

Background Heart failure with preserved ejection fraction is increasing in prevalence and is
associated with a high symptom burden and functional impairment, especially in persons …

The American Diabetes Association and the European Association for the Study of Diabetes
have briefly updated their 2018 recommendations on management of hyperglycemia, …

Background Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and
glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of …

Background Lower-respiratory-tract infection is one of the most common acute illnesses
managed in primary care. Few placebo-controlled studies of antibiotics have been done, and …

The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the prior position statements, published in 2012 and 2015, on …

Importance The effect of continuing vs withdrawing treatment with semaglutide, a glucagon-like
peptide 1 receptor agonist, on weight loss maintenance in people with overweight or …